title: Mesenteric and splenic cat-scratch disease during etanercept therapy.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Schiffmann
authors.forename: Yves Marie
authors.initials: YM
authors.lastname: Pers
authors.forename: Cédric
authors.initials: C
authors.lastname: Lukas
authors.forename: Bernard
authors.initials: B
authors.lastname: Combe
authors.forename: Jacques
authors.initials: J
authors.lastname: Morel
mesh_terms: D018784:Abdominal Abscess / Q000382:microbiology; D018501:Antirheumatic Agents / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D002372:Cat-Scratch Disease / Q000139:chemically induced*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced*; D018124:Receptors, Tumor Necrosis Factor; D013158:Splenic Diseases / Q000382:microbiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept